Login / Signup

Safety and Effectiveness of SB2 (Infliximab Biosimilar) in Adult Patients with Immune-Mediated Inflammatory Diseases: A Post-Marketing Surveillance in Korea.

Dong W KimYousun LeeGeuntae KimSang H KimDae H ChoJeongmin ChoiYong H KwonYounjin ParkWooree ChoiDong-Il Park
Published in: Advances in therapy (2023)
This PMS study of the IFX-biosimilar SB2 in Korea confirmed the safety and effectiveness of SB2 in major indications.
Keyphrases
  • randomized controlled trial
  • systematic review
  • public health
  • ulcerative colitis
  • patients with inflammatory bowel disease